Skip to main content
Clinical Trials/TCTR20231019005
TCTR20231019005
Recruiting
Phase 1

Effect of Mozart K.448 on interictal epileptiform discharges in drug-resistant adult epilepsy patients in King Chulalongkorn Memorial hospital

Chulalongkorn Comprehensive Epilepsy Center of Excellence0 sites30 target enrollmentOctober 19, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Drug-resistant epilepsy
Sponsor
Chulalongkorn Comprehensive Epilepsy Center of Excellence
Enrollment
30
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 19, 2023
End Date
February 29, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Chulalongkorn Comprehensive Epilepsy Center of Excellence

Eligibility Criteria

Inclusion Criteria

  • 1\.Age more than 18 years old
  • 2\.Drug\-resistant epilepsy was diagnosed
  • 3\.Stable antiseizure medication dose for 1 months before inclusion

Exclusion Criteria

  • 1\.Patients who refused to participate in the research
  • 2\.Patients who cannot do an EEG according to the 10\-20 principle, such as patients undergoing cranial surgery.
  • 3\.Patients with hearing impairment
  • 4\.Patient was diagnosed with epilepsy caused by progressive neurological disease such as Rasmussen's encephalitis, mitochondrial disorders, inborn error of metabolism, autoimmune\-associated epilepsy, etc.
  • 5\.Patients who tend to be unable to tolerate listening to Mozart K.448, such as those with intellectual disabilities and accompanying behavioral problems.
  • 6\.In the first 4\-hour EEG recording during the first night of the study, there were fewer than 10 interictal epileptiform discharges.
  • 7\.The patient has a history of irregular heart rhythm known as atrial fibrillation.
  • 8\.The patient has a history of having a permanent pacemaker (PPM) implanted.

Outcomes

Primary Outcomes

Not specified

Similar Trials